{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:36:03Z","timestamp":1793093763091,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:00:00Z","timestamp":1793059200000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anaplastic thyroid cancer (ATC) is a rare and aggressive tumor with a historical median survival of less than six months. Most patients have advanced disease at the time of diagnosis. Traditional cytotoxic chemotherapy has not shown survival benefits. Molecular testing and next-generation sequencing are used to identify specific targets for patients with ATC. If positive for\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E mutation, patients can be treated with BRAF\/MEK inhibitors. Other therapies include tyrosine kinase inhibitors (e.g., lenvatinib) and recently immune checkpoint inhibitors which have shown remarkable results in a subset of patients, including when used along with targeted therapy. An illustrative case of a patient with advanced\n                    <jats:italic>BRAF<\/jats:italic>\n                    -mutant ATC (respiratory failure on a ventilator) who recovered with a combination of the anti-PD1 nivolumab and the\n                    <jats:italic>BRAF V600E<\/jats:italic>\n                    targeted drug vemurafenib is shown. Further studies using biomarker-based gene- and immune-targeted agents, including in combination, are needed in ATC.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01524-9","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:03:58Z","timestamp":1783515838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anaplastic thyroid cancer: review of precision therapy options and advances"],"prefix":"10.1038","volume":"10","author":[{"given":"Noor","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"1524_CR1","first-page":"5888","volume":"11","author":"B Lin","year":"2019","unstructured":"Lin, B. et al. The incidence and survival analysis for anaplastic thyroid cancer: A SEER database analysis. Am. J. Transl. Res 11, 5888\u20135896 (2019).","journal-title":"Am. J. Transl. Res"},{"key":"1524_CR2","first-page":"239","volume":"36","author":"I Abe","year":"2021","unstructured":"Abe, I. & Lam, A. K. Y. Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging. Histol. Histopathol. 36, 239\u2013248 (2021).","journal-title":"Histol. Histopathol."},{"key":"1524_CR3","first-page":"44","volume":"4","author":"XM Keutgen","year":"2015","unstructured":"Keutgen, X. M., Sadowski, S. M. & Kebebew, E. Management of anaplastic thyroid cancer. Gland Surg. 4, 44\u201351 (2015).","journal-title":"Gland Surg."},{"key":"1524_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible, K. C. et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid J. Am. Thyroid Assoc. 31, 337\u2013386 (2021).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR5","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1089\/thy.2012.0302","volume":"22","author":"RC Smallridge","year":"2012","unstructured":"Smallridge, R. C. et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid J. Am. Thyroid Assoc. 22, 1104\u20131139 (2012).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer, P. C. et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid J. Am. Thyroid Assoc. 28, 79\u201387 (2018).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas, A. et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol. 6, 1397\u20131404 (2020).","journal-title":"JAMA Oncol."},{"key":"1524_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14737140.2018.1417845","volume":"18","author":"A Antonelli","year":"2018","unstructured":"Antonelli, A., Ferrari, S. M. & Fallahi, P. Current and future immunotherapies for thyroid cancer. Expert Rev. Anticancer Ther. 18, 149\u2013159 (2018).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1524_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2482-13-S2-S44","volume":"13","author":"A Guerra","year":"2013","unstructured":"Guerra, A. et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg. 13, S44 (2013).","journal-title":"BMC Surg."},{"key":"1524_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: Updated analysis from the phase II ROAR basket study. Ann. Oncol. J. Eur. Soc. Med. Oncol. 33, 406\u2013415 (2022.","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"1524_CR11","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1007\/s12325-020-01433-8","volume":"37","author":"S Takahashi","year":"2020","unstructured":"Takahashi, S. et al. Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Adv. Ther. 37, 3850\u20133862 (2020).","journal-title":"Adv. Ther."},{"key":"1524_CR12","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","volume":"10","author":"ME Cabanillas","year":"2024","unstructured":"Cabanillas, M. E. et al. Anti\u2013programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: A nonrandomized clinical trial. JAMA Oncol. 10, 1672 (2024).","journal-title":"JAMA Oncol."},{"key":"1524_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3803\/EnM.2022.1553","volume":"37","author":"CK Jung","year":"2022","unstructured":"Jung, C. K., Bychkov, A. & Kakudo, K. Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach. Endocrinol. Metab. Seoul. Korea 37, 703\u2013718 (2022).","journal-title":"Endocrinol. Metab. Seoul. Korea"},{"key":"1524_CR14","doi-asserted-by":"publisher","first-page":"e220293","DOI":"10.1530\/ERC-22-0293","volume":"30","author":"C Christofer Juhlin","year":"2023","unstructured":"Christofer Juhlin, C., Mete, O. & Baloch, Z. W. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr. Relat. Cancer 30, e220293 (2023).","journal-title":"Endocr. Relat. Cancer"},{"key":"1524_CR15","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato, S. et al. RET aberrations in diverse cancers: Next-generation sequencing of 4,871 patients. Clin. Cancer Res J. Am. Assoc. Cancer Res 23, 1988\u20131997 (2017).","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res"},{"key":"1524_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221101691","volume":"14","author":"DM Vodopivec","year":"2022","unstructured":"Vodopivec, D. M. & Hu, M. I. RET kinase inhibitors for RET-altered thyroid cancers. Ther. Adv. Med Oncol. 14, 17588359221101691 (2022).","journal-title":"Ther. Adv. Med Oncol."},{"key":"1524_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch, Z. W. et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33, 27\u201363 (2022).","journal-title":"Endocr. Pathol."},{"key":"1524_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1677\/ERC-08-0154","volume":"16","author":"RC Smallridge","year":"2009","unstructured":"Smallridge, R. C., Marlow, L. A. & Copland, J. A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16, 17\u201344 (2009).","journal-title":"Endocr. Relat. Cancer"},{"key":"1524_CR19","first-page":"e48","volume":"22","author":"EF Cleere","year":"2024","unstructured":"Cleere, E. F., Prunty, S. & O\u2019Neill, J. P. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease. Surg. J. R. Coll. Surg. Edinb. Irel. 22, e48\u2013e53 (2024).","journal-title":"Surg. J. R. Coll. Surg. Edinb. Irel."},{"key":"1524_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2020.01.005","volume":"61","author":"N Pozdeyev","year":"2020","unstructured":"Pozdeyev, N., Rose, M. M., Bowles, D. W. & Schweppe, R. E. Molecular therapeutics for anaplastic thyroid cancer. Semin Cancer Biol. 61, 23\u201329 (2020).","journal-title":"Semin Cancer Biol."},{"key":"1524_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/cen.15098","volume":"101","author":"Y Saito","year":"2024","unstructured":"Saito, Y. et al. Comprehensive genomic profiling from C-CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1. Clin. Endocrinol. (Oxf.) 101, 170\u2013179 (2024).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"1524_CR22","doi-asserted-by":"publisher","first-page":"E497","DOI":"10.1210\/jc.2013-1512","volume":"99","author":"JM Pita","year":"2014","unstructured":"Pita, J. M., Figueiredo, I. F., Moura, M. M., Leite, V. & Cavaco, B. M. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 99, E497\u2013E507 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1524_CR23","first-page":"1359","volume":"17","author":"S Begum","year":"2004","unstructured":"Begum, S. et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod. Pathol. J. U S Can. Acad. Pathol. Inc. 17, 1359\u20131363 (2004).","journal-title":"Mod. Pathol. J. U S Can. Acad. Pathol. Inc."},{"key":"1524_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaoto.2022.5045","volume":"149","author":"SS Wu","year":"2023","unstructured":"Wu, S. S. et al. Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer: A Single-Institution 21-Year Experience. JAMA Otolaryngol. Neck Surg. 149, 300 (2023).","journal-title":"JAMA Otolaryngol. Neck Surg."},{"key":"1524_CR25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","volume":"24","author":"N Pozdeyev","year":"2018","unstructured":"Pozdeyev, N. et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin. Cancer Res J. Am. Assoc. Cancer Res 24, 3059\u20133068 (2018).","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res"},{"key":"1524_CR26","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/sj.bjc.6603764","volume":"96","author":"T Takano","year":"2007","unstructured":"Takano, T., Ito, Y., Hirokawa, M., Yoshida, H. & Miyauchi, A. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br. J. Cancer 96, 1549\u20131553 (2007).","journal-title":"Br. J. Cancer"},{"key":"1524_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/his.14144","volume":"77","author":"TY Chen","year":"2020","unstructured":"Chen, T. Y., Lorch, J. H., Wong, K. S. & Barletta, J. A. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma. Histopathology 77, 314\u2013320 (2020).","journal-title":"Histopathology"},{"key":"1524_CR28","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/j.clon.2022.10.017","volume":"35","author":"C Lorimer","year":"2023","unstructured":"Lorimer, C. et al. Dabrafenib and trametinib therapy for advanced anaplastic thyroid cancer - real-world outcomes from UK centres. Clin. Oncol. R. Coll. Radio. G B 35, e60\u2013e66 (2023).","journal-title":"Clin. Oncol. R. Coll. Radio. G B"},{"key":"1524_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah, V. et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 36, 7\u201313 (2018).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"1524_CR30","first-page":"5342","volume":"12","author":"CF Chang","year":"2022","unstructured":"Chang, C. F. et al. The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: A multi-institutional retrospective study in Taiwan. Am. J. Cancer Res 12, 5342\u20135350 (2022).","journal-title":"Am. J. Cancer Res"},{"key":"1524_CR31","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med 373, 726\u2013736 (2015).","journal-title":"N. Engl. J. Med"},{"key":"1524_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/ejendo\/lvac011","volume":"188","author":"TN Da Silva","year":"2023","unstructured":"Da Silva, T. N. et al. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study. Eur. J. Endocrinol. 188, 31\u201338 (2023).","journal-title":"Eur. J. Endocrinol."},{"key":"1524_CR33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847\u2013856 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"1524_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.36401\/JIPO-22-9","volume":"5","author":"NJ Bevins","year":"2022","unstructured":"Bevins, N. J. et al. Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1\/PD-L1 immunotherapy. J. Immunother. Precis Oncol. 5, 90\u201397 (2022).","journal-title":"J. Immunother. Precis Oncol."},{"key":"1524_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman, A., Patel, S. P. & Kurzrock, R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat. Rev. Clin. Oncol. 14, 203\u2013220 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1524_CR36","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2016-3756","volume":"102","author":"AV Chintakuntlawar","year":"2017","unstructured":"Chintakuntlawar, A. V. et al. Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: Results from a retrospective study. J. Clin. Endocrinol. Metab. 102, 1943\u20131950 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1524_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/his.13230","volume":"71","author":"K Zwaenepoel","year":"2017","unstructured":"Zwaenepoel, K. et al. CD70 and PD-L1 in anaplastic thyroid cancer\u2013promising targets for immunotherapy. Histopathology 71, 357\u2013365 (2017).","journal-title":"Histopathology"},{"key":"1524_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","volume":"64","author":"S Cantara","year":"2019","unstructured":"Cantara, S. et al. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine 64, 122\u2013129 (2019).","journal-title":"Endocrine"},{"key":"1524_CR39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","volume":"4","author":"AM Goodman","year":"2018","unstructured":"Goodman, A. M. et al. Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol. 4, 1237\u20131244 (2018).","journal-title":"JAMA Oncol."},{"key":"1524_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 38, 1\u201310 (2020).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"1524_CR41","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","volume":"31","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V., Solit, D. B., Chan, T. A. & Kurzrock, R. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians. Ann. Oncol. J. Eur. Soc. Med. Oncol. 31, 1115\u20131118 (2020).","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"1524_CR42","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598\u20132608 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"1524_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10680-5","volume":"10","author":"SK Yoo","year":"2019","unstructured":"Yoo, S. K. et al. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat. Commun. 10, 2764 (2019).","journal-title":"Nat. Commun."},{"key":"1524_CR44","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa, I. et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest 126, 1052\u20131066 (2016).","journal-title":"J. Clin. Invest"},{"key":"1524_CR45","doi-asserted-by":"publisher","first-page":"929091","DOI":"10.3389\/fendo.2022.929091","volume":"13","author":"A Garcia-Alvarez","year":"2022","unstructured":"Garcia-Alvarez, A., Hernando, J., Carmona-Alonso, A. & Capdevila, J. What is the status of immunotherapy in thyroid neoplasms? Front Endocrinol. 13, 929091 (2022).","journal-title":"Front Endocrinol."},{"key":"1524_CR46","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"1524_CR47","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila, J. et al. PD-1 blockade in anaplastic thyroid carcinoma. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 38, 2620\u20132627 (2020).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"1524_CR48","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1089\/thy.2022.0073","volume":"32","author":"A Hatashima","year":"2022","unstructured":"Hatashima, A. et al. An evaluation of clinical efficacy of immune checkpoint inhibitors for patients with anaplastic thyroid carcinoma. Thyroid J. Am. Thyroid Assoc. 32, 926\u2013936 (2022).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR49","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1089\/thy.2022.0050","volume":"32","author":"NY Lee","year":"2022","unstructured":"Lee, N. Y. et al. A pilot study of durvalumab (MEDI4736) with tremelimumab in combination with image-guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer. Thyroid J. Am. Thyroid Assoc. 32, 799\u2013806 (2022).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR50","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","volume":"38","author":"JH Lorch","year":"2020","unstructured":"Lorch, J. H. et al. A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). J. Clin. Oncol. 38, 6513\u20136513 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1524_CR51","doi-asserted-by":"publisher","unstructured":"Chae Y. K., et al. 270 A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the thyroid tumor cohort. In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; A161.1-A161. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0270 (2020).","DOI":"10.1136\/jitc-2020-SITC2020.0270"},{"key":"1524_CR52","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","volume":"10","author":"K Sehgal","year":"2024","unstructured":"Sehgal, K. et al. Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: A phase 2 nonrandomized clinical trial. JAMA Oncol. 10, 1663 (2024).","journal-title":"JAMA Oncol."},{"key":"1524_CR53","doi-asserted-by":"publisher","first-page":"17194","DOI":"10.18632\/oncotarget.7839","volume":"7","author":"E Brauner","year":"2016","unstructured":"Brauner, E. et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget 7, 17194\u201317211 (2016).","journal-title":"Oncotarget"},{"key":"1524_CR54","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1002\/ijc.32041","volume":"144","author":"V Gunda","year":"2019","unstructured":"Gunda, V. et al. Anti-PD-1\/PD-L1 therapy augments lenvatinib\u2019s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J. Cancer 144, 2266\u20132278 (2019).","journal-title":"Int J. Cancer"},{"key":"1524_CR55","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks, C. et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid J. Am. Thyroid Assoc. 31, 1076\u20131085 (2021).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR56","doi-asserted-by":"publisher","first-page":"S1295","DOI":"10.1016\/j.annonc.2022.07.1726","volume":"33","author":"C Dierks","year":"2022","unstructured":"Dierks, C. et al. 1646MO Phase II ATLEP trial: Final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Ann. Oncol. 33, S1295 (2022).","journal-title":"Ann. Oncol."},{"key":"1524_CR57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/10507256251409138","volume":"36","author":"S Hamidi","year":"2026","unstructured":"Hamidi, S. et al. Real-world experience with lenvatinib plus pembrolizumab in metastatic BRAF wild-type anaplastic thyroid carcinoma. Thyroid\u00ae 36, 153\u2013161 (2026).","journal-title":"Thyroid\u00ae"},{"key":"1524_CR58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","volume":"6","author":"PC Iyer","year":"2018","unstructured":"Iyer, P. C. et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J. Immunother. Cancer 6, 68 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1524_CR59","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1200\/JCO.2024.42.16_suppl.6103","volume":"42","author":"H Zhu","year":"2024","unstructured":"Zhu, H., Liu, S., Shi, Y. & Gui, L. Efficacy and safety of anlotinib combined with sintilizumab in locally advanced or metastatic anaplastic thyroid carcinoma. J. Clin. Oncol. 42, 6103\u20136103 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1524_CR60","doi-asserted-by":"publisher","first-page":"e18070","DOI":"10.1200\/JCO.2024.42.16_suppl.e18070","volume":"42","author":"S Hamidi","year":"2024","unstructured":"Hamidi, S. et al. Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis. J. Clin. Oncol. 42, e18070\u2013e18070 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1524_CR61","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1200\/JCO.2025.43.16_suppl.6008","volume":"43","author":"M Zafereo","year":"2025","unstructured":"Zafereo, M. et al. Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAF m-ATC): A multicenter phase 2 trial. J. Clin. Oncol. 43, 6008\u20136008 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1524_CR62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/cancers15010179","volume":"15","author":"J Yuan","year":"2022","unstructured":"Yuan, J. & Guo, Y. Targeted therapy for anaplastic thyroid carcinoma: advances and management. Cancers 15, 179 (2022).","journal-title":"Cancers"},{"key":"1524_CR63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"M Tahara","year":"2017","unstructured":"Tahara, M. et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 7, 25 (2017).","journal-title":"Front Oncol."},{"key":"1524_CR64","first-page":"210","volume":"173","author":"T Higashiyama","year":"2022","unstructured":"Higashiyama, T. et al. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur. J. Cancer Oxf. Engl. 1990 173, 210\u2013218 (2022).","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"1524_CR65","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1200\/JCO.20.03093","volume":"39","author":"LJ Wirth","year":"2021","unstructured":"Wirth, L. J. et al. Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 39, 2359\u20132366 (2021).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"1524_CR66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1507\/endocrj.EJ20-0287","volume":"68","author":"S Ishihara","year":"2021","unstructured":"Ishihara, S. et al. Treatment of anaplastic thyroid cancer with tyrosine kinase inhibitors targeted on the tumor vasculature: Initial experience in clinical practice. Endocr. J. 68, 63\u201368 (2021).","journal-title":"Endocr. J."},{"key":"1524_CR67","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12020-020-02425-y","volume":"71","author":"M Kim","year":"2021","unstructured":"Kim, M. et al. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer. Endocrine 71, 427\u2013433 (2021).","journal-title":"Endocrine"},{"key":"1524_CR68","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1530\/EJE-20-1482","volume":"184","author":"J Park","year":"2021","unstructured":"Park, J. et al. Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. Eur. J. Endocrinol. 184, 837\u2013845 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"1524_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/ERC-20-0106","volume":"28","author":"C Sparano","year":"2021","unstructured":"Sparano, C. et al. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. Endocr. Relat. Cancer 28, 15\u201326 (2021).","journal-title":"Endocr. Relat. Cancer"},{"key":"1524_CR70","first-page":"7271","volume":"16","author":"H Iwasaki","year":"2018","unstructured":"Iwasaki, H. et al. Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study. Oncol. Lett. 16, 7271\u20137277 (2018).","journal-title":"Oncol. Lett."},{"key":"1524_CR71","first-page":"2859","volume":"34","author":"N Fukuda","year":"2020","unstructured":"Fukuda, N. et al. Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib. Vivo Athens Greece 34, 2859\u20132864 (2020).","journal-title":"Vivo Athens Greece"},{"key":"1524_CR72","doi-asserted-by":"publisher","first-page":"852","DOI":"10.21037\/gs-20-871","volume":"10","author":"H Yamazaki","year":"2021","unstructured":"Yamazaki, H. et al. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma. Gland Surg. 10, 852\u2013860 (2021).","journal-title":"Gland Surg."},{"key":"1524_CR73","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3892\/mco.2020.2190","volume":"14","author":"H Iwasaki","year":"2021","unstructured":"Iwasaki, H., Toda, S., Murayama, D., Kato, S. & Matsui, A. Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis. Mol. Clin. Oncol. 14, 28 (2021).","journal-title":"Mol. Clin. Oncol."},{"key":"1524_CR74","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1089\/thy.2012.0103","volume":"23","author":"P Savvides","year":"2013","unstructured":"Savvides, P. et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid J. Am. Thyroid Assoc. 23, 600\u2013604 (2013).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR75","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1089\/thy.2010.0057","volume":"20","author":"HT Ha","year":"2010","unstructured":"Ha, H. T. et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid J. Am. Thyroid Assoc. 20, 975\u2013980 (2010).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR76","first-page":"110","volume":"76","author":"A Ravaud","year":"2017","unstructured":"Ravaud, A. et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur. J. Cancer Oxf. Engl. 1990 76, 110\u2013117 (2017).","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"1524_CR77","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1210\/jc.2012-1520","volume":"97","author":"KC Bible","year":"2012","unstructured":"Bible, K. C. et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 97, 3179\u20133184 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1524_CR78","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/thy.2007.0120","volume":"18","author":"NA Pennell","year":"2008","unstructured":"Pennell, N. A. et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid J. Am. Thyroid Assoc. 18, 317\u2013323 (2008).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR79","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack, S. G. et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur. J. Endocrinol. 186, 631\u2013643 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"1524_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.727","volume":"12","author":"Q Zhao","year":"2022","unstructured":"Zhao, Q. et al. The central role of a two-way positive feedback pathway in molecular targeted therapies-mediated pyroptosis in anaplastic thyroid cancer. Clin. Transl. Med 12, e727 (2022).","journal-title":"Clin. Transl. Med"},{"key":"1524_CR81","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","volume":"24","author":"SM Lim","year":"2013","unstructured":"Lim, S. M. et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann. Oncol. J. Eur. Soc. Med Oncol. 24, 3089\u20133094 (2013).","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"key":"1524_CR82","first-page":"411","volume":"164","author":"Z Milosevic","year":"2014","unstructured":"Milosevic, Z. et al. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl. Res J. Lab Clin. Med 164, 411\u2013423 (2014).","journal-title":"Transl. Res J. Lab Clin. Med"},{"key":"1524_CR83","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","volume":"24","author":"GJ Hanna","year":"2018","unstructured":"Hanna, G. J. et al. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: A phase II study. Clin. Cancer Res J. Am. Assoc. Cancer Res 24, 1546\u20131553 (2018).","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res"},{"key":"1524_CR84","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fonc.2019.00106","volume":"9","author":"EJ Harris","year":"2019","unstructured":"Harris, E. J. et al. Everolimus in anaplastic thyroid cancer: A case series. Front Oncol. 9, 106 (2019).","journal-title":"Front Oncol."},{"key":"1524_CR85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1089\/thy.2008.0321","volume":"19","author":"CJ Mooney","year":"2009","unstructured":"Mooney, C. J. et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid J. Am. Thyroid Assoc. 19, 233\u2013240 (2009).","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1524_CR86","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1210\/jc.2013-1106","volume":"98","author":"RC Smallridge","year":"2013","unstructured":"Smallridge, R. C. et al. Efatutazone, an oral PPAR-\u03b3 agonist, in combination with paclitaxel in anaplastic thyroid cancer: Results of a multicenter phase 1 trial. J. Clin. Endocrinol. Metab. 98, 2392\u20132400 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1524_CR87","doi-asserted-by":"publisher","first-page":"e250024","DOI":"10.1530\/ETJ-25-0024","volume":"14","author":"A Ry\u0161ka","year":"2025","unstructured":"Ry\u0161ka, A. et al. Molecular predictive biomarker testing in advanced thyroid cancer \u2013 a European consensus. Eur. Thyroid J. 14, e250024 (2025).","journal-title":"Eur. Thyroid J."},{"key":"1524_CR88","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","volume":"36","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth, J. D. et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIa multiple basket study. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 36, 536\u2013542 (2018).","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"1524_CR89","unstructured":"Shu Mei K. Study of personalized cancer therapy to determine response and toxicity. Accessed March 16, 2026. https:\/\/clinicaltrials.gov\/study\/NCT02478931."},{"key":"1524_CR90","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1634\/theoncologist.2017-0096","volume":"22","author":"R Kollipara","year":"2017","unstructured":"Kollipara, R., Schneider, B., Radovich, M., Babu, S. & Kiel, P. J. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. Oncologist 22, 1149\u20131151 (2017).","journal-title":"Oncologist"},{"key":"1524_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01038-w","volume":"9","author":"D Nishizaki","year":"2025","unstructured":"Nishizaki, D. et al. Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection. Npj Precis Oncol. 9, 253 (2025).","journal-title":"Npj Precis Oncol."},{"key":"1524_CR92","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijscr.2016.06.013","volume":"25","author":"S Eckhardt","year":"2016","unstructured":"Eckhardt, S. et al. Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature. Int J. Surg. Case Rep. 25, 174\u2013178 (2016).","journal-title":"Int J. Surg. Case Rep."},{"key":"1524_CR93","first-page":"1496","volume":"53","author":"AK Behnagh","year":"2024","unstructured":"Behnagh, A. K. et al. An overview on prevalence and detection approaches of BRAF V600E mutation in anaplastic thyroid carcinoma: A systematic review and meta-analysis. Iran. J. Public Health 53, 1496\u20131507 (2024).","journal-title":"Iran. J. Public Health"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01524-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01524-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01524-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:02:14Z","timestamp":1793091734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01524-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1524"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01524-9","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"408"}}